BTG's Louise Makin On Joining IO Agents And Localized Intervention

 
• By Sten Stovall

BTG's CEO says combining novel immuno-oncology therapies with image-guided, minimally invasive therapies could deliver treatments where needed while lowering overall treatment costs.

Louise Makin
BTG CEO Says Joining Interventional Oncology And I/O Agents Is Promising • Source: BTG PLC

More from Strategy

More from Business